Publications

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Caffeine, acetanilide, and methoxyresorufin metabolism by rat and human CYP1A2 SUPERSOMES and their inhibition by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). Dioxin 2003, Boston, MA, 2003. Organohalogen Compounds 64:324-327.

Grasty RC, Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research B 68(3):5.

Panko JM. Mold problems in buildings. Solving water intrusion and mold problems in Pennsylvania. Lorman Education Services, Altoona, PA, November 5, 2003.

Panko JM. AWMA/Healthy indoor partnerships. International Conference on Indoor Air Quality/Health Indoor Environment, Mold Contamination Case Studies, 2003.

Panko JM, Shay EC, Unice KM. Risk perception: The reoccupancy of Lower Manhattan office space following the national tragedies of September 11, 2001. Poster at the Society for Risk Analysis Annual Conference, December 2003.

Clewell H, Crump K, Covington T, Gentry R, Yeager J. A risk assessment for inhaled arsenic based on urinary arsenic concentration using a pharmacokinetic model. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2003.

Haws L. Permitting of hazardous waste combustion facilities in the state of Texas: Human health risks associated with fugitive emissions sources. Presented at the Texas Chemical Council Quarterly Meeting. Houston, TX, August 2002.

Haws L. Texas risk reduction program rule-The basics. Question and Answer Forum Panelist. Presented at the Texas Natural Resource Conservation Commission Environmental Trade Fair. Waste Remediation Track, Austin, TX, May 2002.

Haws L. Toxicology and risk assessment resources and practices in the state of Texas. Presented at the USEPA Region 6 States Risk Assessment Roundtable, Dallas, TX, April 2002.

Perry CS. TRRP Rule – The basics part 2: Human health PCLs and look-up tables. TNRCC Environmental Trade Fair presentation and paper, 2002.

Grasty RC, Grey BE, Thibodeaux J, Lau C, Rogers JM. Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat. Society of Toxicology 41st Annual Meeting, Nashville, TN, March 2002.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Society of Toxicology 41st Annual Meeting, Nashville, TN, March 2002.

Gentry R, Teeguarden J, Sarangapani R, Covington T, Lawrence G, McDonald T, Shipp A, Clewell H. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences in tissue dosimetry. Poster presented at the Society of Toxicology Annual Meeting, Nashville, TN, March 2002.

Covington TR, Teeguarden J, Sarangapani R, Gentry PR, Clewell HJ. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Presentation at the Annual Society for Risk Analysis Conference, Seattle, WA, December 2001.

Haws, L. Risk assessment coordination between EPA and states panelist. Presented at the USEPA Regional Risk Assessors Annual Conference. Bandera, TX, May 2001.

Haws L. Texas risk reduction program rule-Practical applications. Question and Answer Forum Panelist. Presented at the Texas Natural Resource Conservation Commission Environmental Trade Fair, Waste Remediation Track, Austin, TX, April 2001.

Tachovsky JA, McCoy JT, Haws LC. Development and implementation of probabilistic risk assessment protocol in Texas. Presented at the 94th AWMA Conference, Orlando, FL, June 2001.

Grant RL, Morrill D, Manis D, Tachovsky A, Haws LC. The Texas combustion project: Review of trial burn/risk burn plans and reports. International Conference on Incineration and Thermal Treatment Technologies, Portland, OR, May 2000.

Tachovsky JA, Haws LC, Hofelt CS, McCoy JT. 2000. Risk assessment implementation in Texas. International Conference on Incineration and Thermal Treatment Technologies, Portland, OR, May 2000.

Urban JD, Mailman RB. Functional selectivity as a mechanism of action for newer atypical antipsychotic drugs. Presented at Merck, West Point, PA, 2005.